Cargando…
A multi-centre, post-marketing surveillance study of Vi polysaccharide–tetanus toxoid conjugate vaccine (Typbar TCV®) in India
A typhoid Vi capsular-polysaccharide tetanus toxoid conjugate vaccine (Typbar-TCV®) was recommended by the World Health Organization for use in children >6 months of age. The present post-marketing surveillance study was intended to assess the clinical safety of approximately 11 million doses of...
Autores principales: | Reddy, Raghu, Reddy, Bhargav, Sarangi, Vamshi, Reddy, Siddharth, Ella, Raches, Vadrevu, Krishna Mohan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920194/ https://www.ncbi.nlm.nih.gov/pubmed/34242128 http://dx.doi.org/10.1080/21645515.2021.1947761 |
Ejemplares similares
-
Safety, immunogenicity and non-interference of concomitant Typhoid Vi capsular polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV®) and measles or measles-mumps-rubella vaccines in 8–9 months-old Indian children
por: Vadrevu, Krishna Mohan, et al.
Publicado: (2022) -
Immunogenicity and safety of reduced-antigen tetanus, diphtheria and acellular pertussis vaccination in adults treated for obstructive airway diseases
por: Van den Steen, Peter, et al.
Publicado: (2023) -
Waning rate of immunity and duration of protective immunity against diphtheria toxoid as a function of age and number of doses: Systematic review and quantitative data analysis
por: Kitamura, Noriko, et al.
Publicado: (2022) -
A multicenter, single-blind, randomized, phase-2/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E’s Vi-capsular polysaccharide-CRM(197) conjugate typhoid vaccine (TyphiBEV(TM)) in healthy infants, children, and adults in comparison with a licensed comparator
por: Thuluva, Subhash, et al.
Publicado: (2022) -
ASVAC2022 : 8(th) Asian Vaccine Conference
por: Galagoda, Geethani C. S., et al.
Publicado: (2023)